Tech Company Financing Transactions
Adagio Therapeutics Funding Round
On 4/20/2021, Adagio Therapeutics announced $336 million in Series C funding from RA Capital, Adimab and ArrowMark Partners.
Transaction Overview
Company Name
Announced On
4/20/2021
Transaction Type
Venture Equity
Amount
$336,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds for continued advancement of ADG20, its lead clinical candidate being developed as a single agent for both the treatment and prevention of COVID-19, the disease caused by the virus SARS-CoV-2, as well potential future coronaviruses.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
303 Wyman St. 300
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Overview
Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs, and can be used as both therapeutic and durable prophylactic treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tillman Gerngross
Chief Financial Officer
Jane Henderson
Chief Medical Officer
Lynn Connolly
Chief Operating Officer
Halley Gilbert
Chief Scientific Officer
Laura Walker
Chief Technical Officer
Becky Dabora
VP - Bus. Development
Ellie Hershberger
VP - Bus. Development
Eric Kimble
Browse more venture capital transactions:
Prev: 4/20/2021: Virta Health venture capital transaction
Next: 4/21/2021: Candex venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs